These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1292 related articles for article (PubMed ID: 24018362)

  • 1. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbon nanotubes for delivery of small molecule drugs.
    Wong BS; Yoong SL; Jagusiak A; Panczyk T; Ho HK; Ang WH; Pastorin G
    Adv Drug Deliv Rev; 2013 Dec; 65(15):1964-2015. PubMed ID: 23954402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.
    Gan CW; Feng SS
    Biomaterials; 2010 Oct; 31(30):7748-57. PubMed ID: 20673685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical translation of immunoliposomes for cancer therapy: recent perspectives.
    Wang D; Sun Y; Liu Y; Meng F; Lee RJ
    Expert Opin Drug Deliv; 2018 Sep; 15(9):893-903. PubMed ID: 30169978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
    Shmeeda H; Tzemach D; Mak L; Gabizon A
    J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.
    Cruz LJ; Tacken PJ; Fokkink R; Figdor CG
    Biomaterials; 2011 Oct; 32(28):6791-803. PubMed ID: 21724247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
    Hafner AM; Corthésy B; Merkle HP
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
    Han L; Huang R; Liu S; Huang S; Jiang C
    Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
    Zhong Y; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
    Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
    J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.
    Heidel JD; Yu Z; Liu JY; Rele SM; Liang Y; Zeidan RK; Kornbrust DJ; Davis ME
    Proc Natl Acad Sci U S A; 2007 Apr; 104(14):5715-21. PubMed ID: 17379663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy.
    Vijayakumar MR; Muthu MS; Singh S
    Expert Opin Drug Deliv; 2013 Apr; 10(4):529-43. PubMed ID: 23316695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal nanomedicines in the treatment of prostate cancer.
    Kroon J; Metselaar JM; Storm G; van der Pluijm G
    Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT.
    Tang J; Zhang L; Liu Y; Zhang Q; Qin Y; Yin Y; Yuan W; Yang Y; Xie Y; Zhang Z; He Q
    Int J Pharm; 2013 Sep; 454(1):31-40. PubMed ID: 23850793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting toxicity and efficacy of polymeric nanomedicines.
    Igarashi E
    Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.
    Eljack S; David S; Faggad A; Chourpa I; Allard-Vannier E
    Int J Pharm X; 2022 Dec; 4():100126. PubMed ID: 36147518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.